New hepatitis b drug shows promise in large trial

NCT ID NCT07203118

Ongoing Disease control Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medication called hepenofovir fumarate (HTS) for people with chronic hepatitis B, a long-term liver infection. About 1,444 adults aged 18-65 who have not been treated before (or stopped treatment at least 6 months ago) will take one of three doses of HTS or the standard drug TAF daily. The goal is to see which dose works best and is safest, with the hope of offering a new treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hepenofovir fumarate (HTS)
What this could lead to: If successful, this could provide a new once-daily pill option to control chronic hepatitis B, potentially with better safety or efficacy than current treatments.
What could go wrong: This is an early-to-mid stage trial, so the drug may not prove more effective or safer than existing therapy. Side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Locations

The First Hospital of Jilin University

Jilin City, changchun, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.